The Turkish Version of the Simple Physical Activity Questionnaire (SIMPAQ) (SIMPAQ)

August 20, 2020 updated by: Aybike Senel, Istanbul University - Cerrahpasa (IUC)

The Reliability and Validity of the Turkish Version of the Simple Physical Activity Questionnaire (SIMPAQ)

The Simple Physical Activity Questionnaire (SIMPAQ) was originally developed in English to assess physical activity level particularly people with mental illnesses. The purpose of this study was to translate and cross-culturally adapt the SIMPAQ into Turkish and investigate its psychometric properties.

Study Overview

Status

Completed

Detailed Description

The Simple Physical Activity Questionnaire (SIMPAQ) was originally developed in English to assess physical activity level particularly people with mental illnesses. The purpose of this study was to translate and cross-culturally adapt the SIMPAQ into Turkish and investigate its psychometric properties. Eighty individuals with mental illnesses (major depression, bipolar disorder, anxiety disorder, schizophrenia, alcohol and substance addiction) will include. For cross-cultural adaptation and validation procedure, developers' manual in the official site will be followed (http://www.simpaq.org/). Within a 5-to-7-day period after the first assessment, the participants completed the Turkish version of the SIMPAQ to evaluate test-retest reliability. Cronbach's alpha (α) was used to assess internal consistency. The correlations with the Turkish version of the International Physical Activity-Short Form (IPAQ-SF) and Brief Psychiatric Rating Scale (BPRS) and Turkish version of the DSM-5 Self-Rated Level 1 Cross-Cutting Symptom Scale-Adult Version (DSM XC) will determine to check the validity.

Study Type

Observational

Enrollment (Actual)

81

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey, 34500
        • Istanbul University-Cerrahpasa

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 58 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

This study will include 80 patients diagnosed with major depression, bipolar disorder, anxiety disorder, schizophrenia, alcohol and substance addiction by the psychiatrists in Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital, University of Health Sciences. The individuals who volunteers and meets the inclusion criteria will be included in the study.

Description

Inclusion Criteria:

Aged between 18 and 60 years Being a volunteer to participate Being an outpatient or inpatient at the place of the study Being diagnosed with major depression, bipolar disorder, anxiety disorder, schizophrenia, alcohol and substance addiction according to DSM-5 or ICD.

Exclusion Criteria:

Having cognitive impairment Having disabilities in understanding, speaking and reading Turkish Having vision and / or hearing problems

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Simple Physical Activity Questionnaire
Time Frame: Baseline (First assessment)
The SIMPAQ is a reliable and valid tool to assess physical activity in people with mental illness. The 5-item SIMPAQ was designed to capture activity over a representative 24-h period from the previous 7-days. Time spent in bed overnight, time sedentary, including napping, time spent walking, time spent exercising and time engaged in incidental activity are questioned and the sum of them should be approximately 24 h. This structure of the SIMPAQ provides interviewers to understand under or over-reporting. For an estimate of total self-reported moderate-vigorous physical activity (MVPA) time, time spent walking and exercising were combined to provide total MVPA (hours per week).
Baseline (First assessment)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Simple Physical Activity Questionnaire
Time Frame: Within a 5-to-7-day period after the first assessment (Second assessment)
The SIMPAQ is a reliable and valid tool to assess physical activity in people with mental illness. The 5-item SIMPAQ was designed to capture activity over a representative 24-h period from the previous 7-days. Time spent in bed overnight, time sedentary, including napping, time spent walking, time spent exercising and time engaged in incidental activity are questioned and the sum of them should be approximately 24 h. This structure of the SIMPAQ provides interviewers to understand under or over-reporting. For an estimate of total self-reported moderate-vigorous physical activity (MVPA) time, time spent walking and exercising were combined to provide total MVPA (hours per week).
Within a 5-to-7-day period after the first assessment (Second assessment)
International Physical Activity Questionnaire-Short Form
Time Frame: Baseline (First assessment)
International Physical Activity Questionnaire-Short Form (IPAQ-SF) is a self-report questionnaire that assesses PA in the last 7 days. IPAQ-SF provides information on walking, moderate and vigorous activities and time spent sitting, within a week.
Baseline (First assessment)
Brief Psychiatric Rating Scale
Time Frame: Baseline (First assessment)
Brief Psychiatric Rating Scale (BPRS) is a valid 18-item quantitative scale for assessing psychopathology and its severity. Each item is measured on a five-point scale (0 = none to 4 = very severe), with lower scores meaning a lower severity of the symptom.
Baseline (First assessment)
DSM-5 Level 1 Cross-Cutting Symptom Measure-Adult
Time Frame: Baseline (First assessment)
DSM-5 Level 1 Cross-Cutting Symptom Measure-Adult (DSM XC) comprises 23 self-rated symptoms that capture 13 mental health domains. Respondents indicate how much (or how often) they have been bothered by each symptom in the prior two weeks using a five-point response scale (none, not at all to severe, nearly every day). A score of 2 or higher in most domains, except substance use (score of 1 or higher) is suggestive of clinically-relevant mental health problems.
Baseline (First assessment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Ebru KAYA MUTLU, PT, PhD, Istanbul University-Cerrahpasa

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 30, 2020

Primary Completion (Actual)

July 30, 2020

Study Completion (Actual)

August 2, 2020

Study Registration Dates

First Submitted

June 22, 2020

First Submitted That Met QC Criteria

June 22, 2020

First Posted (Actual)

June 23, 2020

Study Record Updates

Last Update Posted (Actual)

August 24, 2020

Last Update Submitted That Met QC Criteria

August 20, 2020

Last Verified

August 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Psychiatric Disorder

3
Subscribe